InspireMD (NYSE:NSPR) versus Nyxoah (NASDAQ:NYXH) Head-To-Head Review

Nyxoah (NASDAQ:NYXH) and InspireMD (NYSE:NSPR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Nyxoah and InspireMD’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-443.16%	-178.90%	-81.83%
InspireMD	-413.96%	-69.42%	-57.68%

Earnings & Valuation

This table compares Nyxoah and InspireMD”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33 million	2.89	-$101.92 million	($2.52)	-0.34
InspireMD	$10.84 million	2.98	-$19.92 million	($0.64)	-1.09

InspireMD has lower revenue, but higher earnings than Nyxoah. InspireMD is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Nyxoah and InspireMD, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1	1	2	0	2.25
InspireMD	0	0	3	0	3.00

Nyxoah presently has a consensus price target of $3.55, suggesting a potential upside of 320.02%. InspireMD has a consensus price target of $4.50, suggesting a potential upside of 546.55%. Given InspireMD’s stronger consensus rating and higher possible upside, analysts plainly believe InspireMD is more favorable than Nyxoah.

Volatility and Risk

Nyxoah has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Institutional & Insider Ownership

44.8% of InspireMD shares are held by institutional investors. 17.1% of Nyxoah shares are held by company insiders. Comparatively, 25.0% of InspireMD shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

InspireMD beats Nyxoah on 11 of the 14 factors compared between the two stocks.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.